Dublin, Dec. 19, 2022 (GLOBE NEWSWIRE) -- The "Leiomyosarcoma - Pipeline Insight, 2022" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Leiomyosarcoma - Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 18+ pipeline drugs in Leiomyosarcoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The assessment part of the report embraces, in depth Leiomyosarcoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Leiomyosarcoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Leiomyosarcoma.
In the coming years, the Leiomyosarcoma market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
The companies and academics that are working to assess challenges and seek opportunities that could influence Leiomyosarcoma R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
A detailed portfolio of major pharma players who are involved in fueling the Leiomyosarcoma treatment market. Several potential therapies for Leiomyosarcoma are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Leiomyosarcoma market size in the coming years.
Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Leiomyosarcoma) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Leiomyosarcoma Emerging Drugs Chapters
This segment of the Leiomyosarcoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Leiomyosarcoma Emerging Drugs
Unesbulin (PTC596): PTC Therapeutics
Unesbulin is an investigational oral tubulin binding agent that arrests tumor cells in G2/M phase, including cancer stem cells, through the action of inhibiting tubulin polymerization. Unesbulin was discovered through PTC's proprietary discovery platform. Currently, it is in Phase II/III stage of clinical trial evaluation to treat Leiomyosarcoma.
TTI-621: Trillium Therapeutics
TTI-621 (SIRPa-IgG1 Fc) is a decoy receptor that blocks CD47 and delivers an activating signal to effector cells such as macrophages through its IgG1 Fc region. This activating signal, which increases the likelihood of monotherapy activity, together with a lack of unwanted binding to red blood cells, provides TTI-621 with the potential to be the best-in-class CD47 blocking agent. Currently, it is in Phase II stage of clinical trial evaluation to treat Leiomyosarcoma.
Leiomyosarcoma: Therapeutic Assessment
This segment of the report provides insights about the different Leiomyosarcoma drugs segregated based on following parameters that define the scope of the report, such as:
Major Players in Leiomyosarcoma
There are approx. 18+ key companies which are developing the therapies for Leiomyosarcoma. The companies which have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase II/III include, PTC Therapeutics.
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Products have been categorized under various ROAs such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
- Molecule Type
Products have been categorized under various Molecule types such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
- Product Type
Leiomyosarcoma Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Key Players
- PTC Therapeutics
- Trillium Therapeutics
- Philogen
- Jazz Pharmaceuticals
- Clovis Oncology
- Bristol-Myers Squibb
- Merck KGaA
- Novartis
- Viracta Therapeutics, Inc.
- OncoResponse, Inc.
- Incyte Corporation
- BioAtla, Inc.
- EMD Serono
- TRACON Pharmaceuticals
- APIM Therapeutics
Key Products
- Unesbulin (PTC596)
- TTI-621
- L19TNF
- Lurbinectedin
- Rucaparib
- Nivolumab
- Avelumab
- Pazopanib
- Eribulin
- Nanatinostat
- OR2805
- Itacitinib
- CAB-AXL-ADC
- M6620
- YH001
- ATX-101
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/his3n2
